Ching M C, Schalch D S, Lebda N J
Acta Endocrinol (Copenh). 1975 Jun;79(2):238-47. doi: 10.1530/acta.0.0790238.
The potentiation of the propylthiouracil (PTU)-induced goitrogenesis after chronic administration of small doses of thyroid hormone has been attributed to the high circulating level of thyrotrophin (TSH) or to the re-instatement of insulin. In re-examining this problem radioimmunoassayable concentrations of TSH, thyroxine (T4), insulin, and growth hormone (GH) were observed in sera of rats at sequential intervals after surgical or chemical thyroidectomy and after thyroidectomy and replacement therapy with GH or T4. In addition, TSH, GH or a combination of both hormones were injected into hypophysectomized recipients in a further attempt to delineate the effect of either hormone on the thyroid. As expected, the rate of body growth was inversely proportional to the apparent severity of the hypothyroidism achieved in the several experimental groups. Goitrogenesis was enhanced after T4 treatment but evidently was not the exclusive result of increased blood levels of TSH or insulin. Evidence is presented that suggest the enhancement of goitrogenesis may be a growth phenomenon involving the additive or synergistic action of GH and TSH and possible of other hormones.
长期给予小剂量甲状腺激素后丙硫氧嘧啶（PTU）诱发甲状腺肿作用增强，这归因于促甲状腺激素（TSH）的高循环水平或胰岛素的恢复。在重新审视这个问题时，在手术或化学性甲状腺切除术后以及甲状腺切除术后用生长激素（GH）或甲状腺素（T4）替代治疗后的大鼠血清中，依次观察到可通过放射免疫测定的TSH、T4、胰岛素和生长激素（GH）浓度。此外，将TSH、GH或两种激素的组合注射到垂体切除的受体中，进一步试图确定这两种激素对甲状腺的影响。正如预期的那样，身体生长速率与几个实验组中实现的甲状腺功能减退的明显严重程度成反比。T4治疗后甲状腺肿的发生增强，但显然不是TSH或胰岛素血水平升高的唯一结果。有证据表明，甲状腺肿发生的增强可能是一种生长现象，涉及GH和TSH以及可能其他激素的相加或协同作用。
